Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage ...

Victory Capital Management Inc. purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) ...

The firm increased its portfolio allocation in SYRE by 3,677.71% over the last quarter. VR Adviser holds 2,373K shares representing 6.48% ownership of the company. Rtw Investments holds 2,233K ...

Shares of Spyre Therapeutics (SYRE) have gained 0.9% over the past four weeks to close the last trading session at $22.65, but there could still be a solid upside left in the stock if short-term ...

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, March 6th.Analysts expect Spyre Therapeutics to post ...

JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares ...

Major textile-to-textile (T2T) recyclers have come together to establish the T2T Alliance, a collaborative effort aimed at ...

As a Black, queer, transmasculine, gender expansive, polyamorous, and kinky healing practitioner Syre (he/him) is passionate about working with those who are traditionally marginalized ...

In a bid to support Europe’s circular economy policies such as the Ecodesign for Sustainable Products Regulation (ESPR), ...